Abstract OBJECTIVE The development of disease-modifying drugs is limited by OA’s heterogeneity and the challenge of defining clinical endpoints. Serological biomarkers are considered potential surrogate endpoints, but their contribution from single joints to systemic levels in OA patients is unclear. In this exploratory study we longitudinally assessed systemic biomarker levels’ response to tissue damage and […]
Association between type III collagen degradation and local tissue damage of a single joint.
December 1, 2024
Osteoarthr Cartil Open